Fig. 1From: The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patientsWaterfall plot of the PSA changes treated by cabazitaxel. The > 50% PSA decrease rate was 19% (22/118) in total. The PSA decrease rates in > 20 mg/m2 (red) and ≤ 20 mg/m2 (blue) were 29% (11/37) and 14% (11/81), respectively (P = 0.073)Back to article page